|
Identification of cellular heme transport receptors that regulate T cell function |
1R21AI164722-01A1 |
|
NIAID |
2022 |
|
Combating chronic neuroinflammatory disorders by targeting NAC1 |
1R21AI167793-01A1 |
|
NIAID |
2022 |
|
IL-1R1, MMP-9, and EAE |
1R21AI169218-01 |
|
NIAID |
2022 |
|
Monitoring Treatment Efficacy in Leprosy |
1R21AI171254-01 |
|
NIAID |
2022 |
|
Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis |
1R43AI157674-01A1 |
|
NIAID |
2022 |
|
STAT5 tetramerization in autoimmune-mediated neuroinflammation |
1R56AI167972-01 |
|
NIAID |
2022 |
|
Functional protein networks underlying T cell growth, proliferation and differentiation |
2R01AI123193-06 |
|
NIAID |
2022 |
|
Development of a novel accurate therapy for multiple sclerosis |
2R42AI141323-02A1 |
|
NIAID |
2022 |
|
Characterizing Shared Features of Innate Immune Cells across Neurodegenerative Diseases using Single Cell Expression and Chromatin Accessibility Data |
5F30AI157270-02 |
|
NIAID |
2022 |
|
Prioritizing and Characterizing T Cell-Relevant Genetic Variants Associated with Autoimmune Diseases |
5K22AI153648-02 |
|
NIAID |
2022 |